Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer

NCT06820463 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06820463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06820463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
April 24, 2025
Completion date
April 30, 2028
Enrollment
390 (estimated)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer